"They need to set their stall out as to what they want to achieve through central clearing, and the only way to do this is to define what OTC products can be standardized, and those which cannot."
--Declan Ward, executive director at NYSE Liffe, on the need for regulators to define which over-the-counter derivatives should be centrally cleared.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
